Article

Inflammatory lesions in ankylosing spondylitis predict new syndesmophytes

In patients with ankylosing spondylitis (AS), the presence of an active inflammatory lesion at the vertebral corner on MRI is associated with development of new syndesmophytes at the corresponding vertebral corner visible on plain radiography, suggesting a relationship between inflammation and ankylosis. New syndesmophytes will develop from a previous active inflammatory lesion even when the lesion has resolved on follow-up MRI after the start of anti-tumor necrosis factor a (anti–TNF–α) therapy.

In patients with ankylosing spondylitis (AS), the presence of an active inflammatory lesion at the vertebral corner on MRI is associated with development of new syndesmophytes at the corresponding vertebral corner visible on plain radiography, suggesting a relationship between inflammation and ankylosis. New syndesmophytes will develop from a previous active inflammatory lesion even when the lesion has resolved on follow-up MRI after the start of anti-tumor necrosis factor α (anti–TNF-α) therapy.

Maksymowych and associates obtained MRI scans and plain radiographs for 29 patients recruited into randomized placebo-controlled trials of anti–TNF-α therapy. An observational cohort consisted of 41 patients with AS monitored prospectively. Readers blinded to radiographic findings evaluated the MRI scans.

One or more new syndesmophytes developed in 44.4% and 45.5% of patients in the anti–TNF-α therapy and placebo arms of the clinical trial cohort, respectively, and in 27.8% and 34.8% in the anti–TNF-α therapy and standard therapy arms of the observational cohort, respectively. New syndesmophytes developed significantly more frequently in vertebral corners with active inflammation (20%) than in those without inflammation (5.1%).

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.